Analyst Josh Jennings from TD Cowen reiterated a Buy rating on Abbott Laboratories and keeping the price target at $137.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Josh Jennings has given his Buy rating due to a combination of factors, including expectations for Abbott to deliver first‑quarter results broadly in line with guidance despite temporary headwinds from a mild respiratory season and geopolitical unrest. He views a solid start to the year as keeping the company on course to achieve its 2026 targets, with a meaningful portion of growth and catalysts still anticipated in the back half of the year.
Jennings is particularly constructive on Abbott’s medical technology and diagnostics businesses, citing resilient procedure volumes and ongoing franchise strength, while seeing potential for a gradual recovery in nutrition later in the year. Although he recognizes that the Middle East conflict adds some uncertainty, he believes Abbott’s local operating presence limits disruption and that any impact should remain manageable, supporting his favorable risk‑reward view and reinforcing the Buy recommendation.
In another report released on April 8, Barclays also reiterated a Buy rating on the stock with a $144.00 price target.
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABT in relation to earlier this year.